Moderna says construction of its new mRNA vaccine factory in the Montreal area will begin later this year, with production expected to begin by the end of 2024. The vaccine manufacturer is announcing that it has agreed to purchase land in a biotechnology park in Laval, Que., a northern suburb of Montreal, to serve as…
US Government Reaches New Deal With Moderna for 65 Million COVID-19 Vaccine Doses
The U.S. government has reached a new deal with Moderna for 65 million additional COVID-19 vaccine doses, the Biden administration announced on July 29. The deal is valued at $1.7 billion. Moderna will sell doses of its vaccine that target Omicron subvariants, according to the agencies that announced the agreement. The actual contract has not…
Canada Approves First COVID-19 Vaccine for Youngest Kids
Health Canada says it has approved the use of Moderna’s COVID-19 vaccine for children as young as six months old. In a July 14 statement, the federal health regulator announced it has authorized the use of Moderna’s Spikevax COVID-19 vaccine for children 6 months to 5 years of age, making Moderna the first pharmaceutical company permitted…
Review of First COVID-19 Shot for Youngest Kids Expected to Finish Mid-July: Health Canada
Federal health officials are reviewing a submission from Moderna seeking to have its COVID-19 shots approved for children as young as six months old. In a series of tweets on July 5, Health Canada said they expect to make a decision by mid-July on whether or not to approve Moderna’s Spikevax COVID-19 vaccine for children…
Moderna to Open mRNA Research and Manufacturing Centre in UK
U.S. pharmaceutical giant Moderna will build a new mRNA Innovation and Technology Center in the UK in partnership with the UK government, with the aim to start producing vaccines in 2025. Announcing the deal on Wednesday, British Prime Minister Boris Johnson said the UK’s first mRNA research and manufacturing centre will give the country access…
‘Severely Flawed’: Cardiologist Criticizes FDA-Funded Study Suggesting Myocarditis, Pericarditis Risks from COVID-19 Vaccines
“Severely flawed” is a cardiologist’s verdict on a peer-reviewed study funded by the Food and Drug Administration (FDA) suggesting possible risks of developing myocarditis and pericarditis after getting a COVID-19 vaccine. The recent FDA study published on June 11, 2022, used health insurance databases to identify myocarditis or pericarditis hospitalizations occurring in people aged 18…
Studies Suggest Possible Link of Neuromyelitis Optica Diagnosis After COVID-19 Vaccination
Emergent peer-reviewed studies have highlighted the occurrence of neuromyelitis optica after COVID-19 vaccinations, suggesting that the autoimmune disease may be occurring as a vaccine adverse event. The studies’ general findings indicate an occurrence of neuromyelitis optica (NMO) in healthy individuals within around two weeks after Pfizer, Moderna, and AstraZeneca vaccines. In patients already affected by…
FDA Advisory Panel Recommends Moderna and Pfizer COVID-19 Vaccines for Babies, Toddlers
A Food and Drug Administration (FDA) advisory panel on June 15 voted to recommend the FDA give emergency authorization to the Moderna and Pfizer COVID-19 vaccines for children as young as 6 months of age. The panel unanimously voted during a virtual meeting after presentations from the companies and the FDA. The FDA has yet…
FDA Advisers Recommend Moderna’s COVID-19 Vaccine for Older Children
Advisers to the Food and Drug Administration (FDA) on June 14 recommended the agency grant emergency authorization to Moderna’s COVID-19 vaccine for children aged 6 to 17. The advisory panel was asked whether they believe the benefits of the vaccine outweigh the risks, and unanimously voted yes following an eight-hour virtual meeting. The FDA is…
Moderna’s COVID-19 Vaccine Effective in Toddlers, Babies: FDA
Moderna’s COVID-19 vaccine is effective for children as young as 6 months old, Food and Drug Administration (FDA) scientists said in a new analysis published late June 11. “Available data support the effectiveness of the Moderna COVID-19 Vaccine in preventing symptomatic COVID-19 in pediatric age groups from 6 months through 17 years of age,” the…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`